PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2010 June 1.
Published in final edited form as:
PMCID: PMC2796538
NIHMSID: NIHMS126181

Amplification of Coronary Arteriogenic Capacity of Multipotent Stromal Cells by Epidermal Growth factor

Abstract

Objective

We determined if increasing adherence of multipotent stromal cells (MSCs) would amplify their effects on coronary collateral growth (CCG).

Methods and Results

Adhesion was established in cultured coronary endothelials cells (CECS) or MSCs treated with epidermal growth factor (EGF). EGF increased MSCs adhesion to CECs, and increased intercellular adhesion molecule (ICAM-1) or vascular cell adhesion molecule (VCAM-1) expression. Increased adherence was blocked by EGF receptor antagonism or antibodies to the adhesion molecules. To determine if adherent MSCs, treated with EGF, would augment CCG, repetitive episodes of myocardial ischemia (RI) were introduced and CCG was measured from the ratio of collateral-dependent (CZ) and normal zone (NZ) flows. CZ/NZ was increased by MSCs without treatment vs RI-control and was further increased by EGF-treated MSCs. EGF-treated MSCs significantly improved myocardial function vs RI or RI+ MSCs demonstrating that the increase in collateral flow was functionally significant. Engraftment of MSCs into myocardium was also increased by EGF treatment.

Conclusions

These results reveal the importance of EGF in MSCs adhesion to endothelium and suggest that MSCs may be effective therapies for the stimulation of coronary collateral growth when interventions are employed to increase their adhesion and homing (in vitro EGF treatment) to the jeopardized myocardium.

Keywords: angiogenesis, collateral circulation, coronary circulation

Ischemic heart disease (IHD) remains the leading cause of death in the United States.1 A well developed coronary collateral vasculature ameliorates manifestations of IHD, myocardial infarction and sudden death.2,3 Despite the importance of the coronary collateral circulation, the majority of patients fail to develop sufficiently large coronary collateral vessels and thus, are vulnerable to coronary occlusion.

Bone marrow-derived cells were used to repair infarcted myocardium4-7 or to stimulate angiogenesis in peri-infarct regions. Although there is controversy regarding whether multipotent stromal cells (MSCs) from bone marrow exert a beneficial role by transdifferentiation8 or by their paracrine role,9-12 there is no doubt that for any benefit, MSCs must home to injured tissues. Homing of MSCs involves adhesion to the endothelium and then migration through the wall;13,14 however, the underlying mechanisms for homing are not understood. Expression of specific ligands facilitating recruitment of MSCs to an injured site represents the first step in the homing of stem cells. Therefore, amplification of homing and adhesion of MSCs may augment their therapeutic role.

Epidermal growth factor (EGF) or the EGF family member, HB-EGF (heparin-binding epidermal growth factor-like growth factor)is involved in a variety of physiological events: differentiation of human derived MSCs into endothelial cells15, adhesion of fibroblast16, and angiogenesis.17,18,19 Interestingly, EGF-R phosphorylation was involved in cell adhesion,20 induction of VCAM-121 and MMP-922 expression in human smooth muscle cells. Based on these findings we reasoned that EGF may play a role in facilitating homing of MSCs to “injured” areas of the heart, and further the effects of the cells. We sought to determine if MSCs amplify coronary collateral growth, and if enhancing adherence of MSCs would further stimulate CCG. Our results support the concept that MSCs augment coronary collateral growth, and that if they are treated by EGF to enhance expression of adhesion molecules, both their homing to the myocardium and their ability to increase collateral growth are increased.

Materials and Methods

Rat coronary endothelial cells (CECs)

CECs were purchased from VEC technologies Inc and were cultured in MCDB-131 complete medium (VEC technologies) medium. The cells were used from passage 3-7.

Rat multipotent stromal cells (MSCs)

MSCs were harvested from the bone marrow of the femurs and tibias of 6- to 12-month-old Lewis rats by inserting a 21-gauge needle into the shaft of the bone and flushing it with 30 ml of complete α-modified Eagle's medium (MEM) containing 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 25 ng/ml Amphotericin B. Cells were filtered through a 70-μm nylon filter and were plated into one 75 cm2 flask. The cells were grown in complete MEM at 37°C and 5% CO2 for 3 days, the medium was replaced with fresh medium, and the adherent cells were grown to 90% confluency to obtain samples defined as passage zero (P0) cells.23

Adhesion Assay

Adhesion assays were performed using eight-well glass chamber slides (Falcon) on which CECs were plated, reaching confluence and labeled with DiO, 3,3′-dioctadecyloxacarbocyanine perchlorate. All experiments were performed with 1000 cells, MSCs labeled with 1,1′-dioctadecyl-3,3,3′,3′ tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes). After incubation at 37°C (24 hours) cells were washed three times with PBS, and adherent cells were counted in 25 fields/well using epifluorescence microscopy (100×). The number of adherent cells was normalized to the total number of added cells. In some experiments, CECs and MSCs were pretreated for adhesion studies with one of the following substances EGF (10 ng, 50 ng, 100 ng, 1 mg per ml), EGF-R inhibitor AG1478 (1μM), cyclohexamide, an inhibitor of protein synthesis (CHX, 100 ng), anti-VCAM-1 or anti-ICAM-1 (10 μg/ml) hour before and during the adhesion assay.

Western Blotting

After 90% of confluence for CECs and 60% for MSCs, the cells were starved for 48 hrs in MCDB-131 medium with 1% serum for CECs and α-MEM-media without serum for MSCs. Cultured cells were then stimulated with EGF (Sigma) for 16 hrs with and without AG1478 (Sigma Aldrich). Cells were harvested and subjected to western blot analysis using ICAM-1 and VCAM-1 antibodies (Santa Cruz).

Rat Model of Coronary Collateral Growth/Repetitive Ischemia

Three to 4 month old, 300-350g, male Sprague Dawley (SD) rats were used for chronic (10 days) implantation of a pneumatic snare over the left anterior descending coronary artery (LAD), as described by Toyota et al24. MSCs were harvested, labeled with DiI and resuspended in PBS and 8 × 105 cells (in 500 μl over 20 sec) were injected into the LV lumen via (27 G needle) after the implantation of the occluder. As a control for the effect of cell infusion, PBS alone was delivered.

Rats were allowed to recover for 2 to 3 hours before the start of a 10 day repetitive ischemia protocol (RI) as described by Toyota et al24. Rats under RI protocol were divided into 3 groups: RI-control, RI+MSCs, RI+MSCs/EGF-activated. Experimental protocols were approved by the Institutional Animal Care and Use Committee of Northeastern Ohio Universities College of Medicine.

Measurements of collateral blood flow

At the end of RI protocol (after 10 day of RI), radioactive microspheres (Perkin Elmer, 15.5 μm, 103Ru ~5 × 105) were injected into the left ventricle (LV) over 20s. Briefly the microspheres were agitated for 15 min, suspended in saline (total volume 150 μl) then injected directly into the left ventricle (LV) apex during LAD occlusion using a 27 G insulin syringe over a 10 s period. The normal and collateral-dependent zones were divided and total weight of each was measured. Radioactivity was measured using a gamma counter and collateral blood flow was measured as a ratio of the cpm/g to the two regions, i.e., CZ/NZ flow ratio.

Echocardiographic Analysis of Cardiac Function

Echocardiographic function was performed after 10 days of repetitive occlusion using a Toshiba Aplio (SSH770 with a fundamental frequency of 8.5, a 1 cm focus, and a frame rate of 300-500 frames/sec. Acquistion and analysis of the images were obtained blinded. For each measurement, three images were analyzed and averaged. LV wall thickness and cavity dimensions were measured by M-mode echocardiography, using American Society of Echocardiography guidelines. Measurements were made from a parasternal long axis view, or from a parasternal short-axis view (papillary level). From these M-mode measurements, LV mass, LV fractional shortening and EF were calculated. Per cent FS was calculated from (LVEDD−LVESD)/LVEDD × 100.

Immunohistochemistry and Immunocytochemistry

CECs or MSCs were stained with EGF, Phospho EGF-R (Cell signaling) antibody and secondary rabbit anti mouse coupled to Alexa Fluor (Molecular Probes). Cellular nuclei were counterstained with DAPI (Molecular Probes). Ten days after IR protocol the rats were anesthetized with pentobarbital and perfused through the abdominal aorta with ice-cold heparanized PBS followed by 4% paraformaldehyde. The hearts were embedded in Tissue-Tek OCT compound and sectioned at 5 μm using a cryostat and mounted onto slides for IHC. Using primary antibodies: rabbit polyclonal anti-human factor VIII (DAKO) to detect endothelial cells; mouse monoclonal anti-smooth muscle alpha-actin (clone 1A4; Sigma) to detect smooth muscle cells. Goat anti-mouse and chicken anti-rabbit AlexaFluor 594 were used as secondary antibodies. To detect the MSCs labeled with DiI engrafted into the myocardium, epifluorescence microscopy was used and numbers of cells were counted in microscopic fields and expressed as numbers of cells per field.

Statistical analysis

Data (mean ± SEM) were analyzed using one-way analysis of variance (ANOVA) followed by Student Newman-Keuls posthoc analysis for statistical comparisons between groups. P<0.05 was considered as significance.

Results

Adhesion of MSCs to CECs

Adhesion of MSCs to CECs was dependent on the period that the MSCs interacted with CECs reaching a maximum at 4 h of incubation (Figure 1A). Incubation of CECs with EGF at concentrations between 10 to1000 ng/ml for 16 h dose-dependently enhanced MSCs adhesion with a maximum at 100 ng/ml (Figure 1B).

Figure 1
A. Adhesion of MSCs to endothelial cells. % of MSCs adherent to CECs after 1, 2, 4 and 24 hours of incubation of both MSCs and CECs. Data are expressed as mean ± SEM. * p<0.05 versus 1 or 2 hr, n = 4. B. Effect of EGF on MSCs adhesion ...

Treatment of MSCs with 100 ng/ml EGF for 16 h (Figure 2A), increased adhesion to CECs (n=4, 70±7%) versus untreated controls (25±3%). When both MSCs and CECs were treated the adhesion was not different than treatment of either cell type. The effect of EGF on MSCs adhesion was EGF receptor-dependent, because AG1478 blocked adhesion. Immunofluorescence revealed EGF-R on endothelial cells and phosphorylation of EGF-R following EGF (Figure 2B). AG1478 inhibited phosphorylation of EGF-R. Figure 2C illustrates that the adhesion of MSCs to CECs induced by EGF was significantly reduced by CHX treatment (29% versus 63%) suggesting that EGF-induced adhesion requires new protein synthesis.

Figure 2
Effect of AG1478 on EGF induced adhesion of MSCs to CECs. A. % of MSCs adherents to CECs after pretreatment of MSCs or CECs with AG1478 prior to the stimulation with EGF, n=4. B. Representative pictures of CECs in CTL, with EGF +/- AG1478 showing the ...

Effect of ICAM-1, VCAM-1 on EGF induced adhesion of MSCs to CECs

VCAM-1 and ICAM-1 antibodies attenuated EGF-induced adhesion of MSCs following treatment of either the MSCs or CECs (Figure 3A). Moreover, treatment of CECs or MSCs with EGF 100 ng induced the expression of ICAM-1 and VCAM-1 suggesting the importance of these molecules in MSCs adhesion (Figure 3B). AG1478 decreased EGF-induced expression of ICAM-1 and VCAM-1 suggesting that ICAM-1 and VCAM-1 induction is mediated by EGF-R signaling.

Figure 3
Importance of VCAM-1 and ICAM-1 on EGF induced adhesion of MSCs to CECs. A. Effect of blocking ICAM-1 and VCAM-1 antibodies on EGF induced MSCs adhesion, % of MSCs adherents to CECs after pretreatment of CECs and MSCs with ICAM-1 and VCAM-1 antibodies. ...

Effect of MSCs on cardiac performance, LV remodeling, and coronary collateral growth

Ten days after RI, the untreated control-RI group exhibited decreased contractility and LV dilation (Figure 4 A). FS was higher in the group treated with MSCs compared to controls (Figure 4 B), and was further increased in the MSCs+EGF group. Administration of MSCs reduced LV cavity dilation as judged by LVEDD and LVESD compared to the controls. However, posterior wall thickness did not differ among the groups (Figure 4B).

Figure 4
Effects of MSCs EGF stimulation on LV remodeling and function. A. Representative M-mode echocardiograms obtained from CTL with no occlusion, Repetitive occlusion RI with MSCs or MSCs+EGF. Arrows show left ventricular chamber. B. Evaluation of LV function: ...

Effect of MSCs on Coronary Arteriogenesis

Coronary collateral growth (indicated by CZ/NZ flow ratio) was increased by MSCs compared to controls. Importantly, CCG was higher in RI group injected with MSCs + EGF compared to untreated MSCs (Figure 5A).

Figure 5
A. Effects of MSCs EGF stimulation on coronary collateral growth. CZ/NZ flow ratio in IR, IR MSCs and IR EGF MSCs treated. Data are expressed as mean ± SEM. * p<0.05 versus IR. # p<0.05 versus IR+MSCs. (IR n=7, IR+ MSC, n = 5, ...

To identify homing of MSCs in the myocardium, cells were visualized using fluorescence microscopy (for Dil). MSCs were found in the heart after 10 days of RI (Figure 5B-E). In non-ischemic tissue we observed few stem cells regardless of treatment: Control, 12±4 vs EGF-treated, 13±3 cells/microscopic field. In ischemic tissue many more of the cells were observed 57±18 cells/microscopic field (P<0.05 vs non-ischemic samples), and the number of cells in ischemic tissue was further augmented by EGF treatment (162±9 cells/field, P<0.05 vs non-ischemic samples and vs ischemic without treatment). Moreover, many of the engrafted MSCs were positive for α-actin SMC or Factor VIII, suggesting their integration in the growing blood vessels as smooth muscle and endothelial cells (Figure 6A-L). It was more difficult to ascertain the proportion of stem cells expressing markers for α-actin or Factor VIII, but generally speaking, the cells expressing these markers appeared to be located in coronary blood vessels. Tissue sections from hearts (hematoxylin and eosin staining) subjected to these treatments are shown in the online supplement.

Figure 6
A,D: Green, smooth muscle cells labeled with anti-α-actin. G,J: Green, endothelial cells labeled with anti-Von Willebrand factor. B,E,H,K: Red, MSCs labeled with DiI. C,F,I,L: Overlay of the images. Yellow indicates Red labeled MSC co-localizing ...

Discussion

In the recent past, clinical trials have tested therapies involving VEGF or FGF to generate functional coronary collataral vessels,25 but unfortunately these trials failed. The use of stem cells to develop coronary collaterals has potential to provide cells, which can integrate in the new blood vessel, and serve as “paracrine factories” for angiogenic factors.26-29 Multipotent stromal cells represent an attractive candidate for cell-based therapies due to their self renewal capacity and multiple paths of differentiation.30 Moreover MSCs can be harvested from bone marrow, expanded in culture without losing their differentiation potential, and administered autologously to eliminate concerns with rejection.

In the current study we demonstrated that rats treated with MSCs, activated in vitro with EGF, demonstrated amplified homing, increased coronary collateral development and better cardiac function than those without treatment or with untreated MSCs. To our knowledge, this is the first study, reporting the importance of adhesion of MSCs in coronary arteriogenesis.

EGF enhanced adhesion of MSCs to CECs via EGF-R phosphorylation in vitro and the homing of stem cells to the heart. Inhibition of EGF receptor phosphorylation in MSCs and CECs blocked the adhesion of MSCs to CECs demonstrating the importance of EGF-R activation. Interestingly, EGF-R phosphorylation is increased in ischemic conditions.31 EGF treatment induced the expression of ICAM-1 and VCAM-1 on MSCs, amplifying adhesion of MSCs to endothelial cells and increasing homing and migration of MSCs to the ischemic territory. We believe the increased adhesion of MSCs produced the salubrious effect on cardiac function and arteriogenesis through increased numbers of cells homing to the ischemic/injured areas of the heart. Although our results support this concept there are some other possibilities. First, it is possible that EGF treatment increases survival of the MSCs, and if more cells survive in vivo, then we would observe more in the myocardium. We do not favor this explanation because the numbers of untreated and EGF treated MSCs were the same in the non-ischemic myocardium. If EGF enhanced survival then we would expect more cells in all locations, but this was not the observation. Second, treatment of MSCs with EGF could enhance their “crosstalk” with resident cells, e.g., smooth muscle, endothelium, and facilitate their transdifferentiation into, or fusion with, another cell type. We have no way of unequivocally addressing this possibility, and enhanced crosstalk may contribute to the mechanims of EGF facilitation of the MSCs therapeutic.

HB-EGF (heparin-binding epidermal growth Factor) was reported to participate in angiogenesis and recruitment of MSCs during embryonic development.17,32,33 However, angiogenesis and arteriogenesis stimulated by ischemia were normal in HB-EGF-/- null mice.31 In this report, HB-EGF-/- mice showed a residual level of EGF-R activation suggesting that other EGF-R ligands could compensate for EGF, which could have masked the contribution of HB-EGF in ischemia-induced angiogenesis or arteriogenesis.

MSCs were reported to regenerate infarcted myocardium;6,34 however, mechanisms underlying therapeutic effects have not been defined with an intense debate over differentiation, paracrine function, and fusion.6,34-38 There is even further debate about the time of administration, as treatment during the time of any surgical procedure (as in our study) could decrease homing to the heart because the cells are being attracted to sites of the surgical wounds. Nonetheless, we still observed significant number of cells in the myocardium subjected to repetitive ischemia. Importantly, we observed co-localization of MSCs with α-actin and Von Willebrand factor suggesting that MSCs participated in the growth of the coronary vasculature, although admittedly we cannot determine if the vessels with MSCs are collaterals.

One final aspect of our results warrants discussion. In previous reports24,39 we have observed that following RI, there is robust growth of coronary collaterals in response to RI without any treatment. In our present study the growth of coronary collaterals in response to RI without any treatment was less than what we have reported. We believe the reason for this discrepancy is related to strain differences among rats. Along this line, different strains of mice show extreme variations in innate collateral development,40 which also then impacts on the eventual development of the collateral circulation.41

Stem cell therapies hold promise for the treatment of ischemic cardiovascular disease. Our study is the first to show that EGF-R activation of MSCs enabled better homing and increased coronary collateral growth in a model of repetitive myocardial ischemia. The betterment of collateral development was also associated with an inhibition of LV remodeling and improved cardiac function. These findings provide a new paradigm for amplifying the effects of administered MSCs (increasing their homing) and this combination of MSCs with EGF may be useful for the treatment of ischemic heart disease.

Supplementary Material

Acknowledgments

The authors would like to thank Jean Carnal and Elizabeth McIlwain for their excellent technical assistance. This work was supported by NIH grants HL32788, HL34286, HL 073755 and P40-RR17447.

Abbreviations

MSCs
multipotent stromal cells
CECs
coronary endothelial cells
CCG
coronary collateral growth
IHD
ischemic heart disease
RI
repetitive ischemia
EGF
epidermal growth factor
EGF-R
epidermal growth factor receptor

Footnotes

Disclosures: none

References

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–1757. [PubMed]
2. Vismara LA, Miller RR, Price JE, Karem R, DeMaria AN, Mason DT. Improved longevity due to reduction of sudden death by aortocoronary bypass in coronary atherosclerosis. Am J Cardiol. 1977;39:919–924. [PubMed]
3. Holmes DR, Jr, Kim LJ, Brooks MM, Kip KE, Schaff HV, Detre KM, Frye RL. The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. J Thorac Cardiovasc Surg. 2007;134:38–46. 46 e31. [PubMed]
4. Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp Biol Med (Maywood) 2006;231:39–49. [PubMed]
5. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195–1201. [PubMed]
6. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705. [PubMed]
7. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci. 2001;938:221–229. discussion 229-230. [PubMed]
8. Gojo S, Gojo N, Takeda Y, Mori T, Abe H, Kyo S, Hata J, Umezawa A. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res. 2003;288:51–59. [PubMed]
9. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun. 2007;354:700–706. [PMC free article] [PubMed]
10. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39:733–742. [PubMed]
11. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428:668–673. [PubMed]
12. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ, Olson L. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A. 2002;99:2199–2204. [PubMed]
13. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108:863–868. [PubMed]
14. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–2749. [PubMed]
15. Gang EJ, Jeong JA, Han S, Yan Q, Jeon CJ, Kim H. In vitro endothelial potential of human UC blood-derived mesenchymal stem cells. Cytotherapy. 2006;8:215–227. [PubMed]
16. Zhang M, Wang MH, Singh RK, Wells A, Siegal GP. Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. J Biol Chem. 1997;272:14139–14146. [PubMed]
17. Abramovitch R, Neeman M, Reich R, Stein I, Keshet E, Abraham J, Solomon A, Marikovsky M. Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett. 1998;425:441–447. [PubMed]
18. Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005;289:H947–959. [PubMed]
19. Sugiura S, Kitagawa K, Tanaka S, Todo K, Omura-Matsuoka E, Sasaki T, Mabuchi T, Matsushita K, Yagita Y, Hori M. Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats. Stroke. 2005;36:859–864. [PubMed]
20. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241–250. [PubMed]
21. Lin WN, Luo SF, Wu CB, Lin CC, Yang CM. Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: Involvement of Src/EGFR/PI3-K/Akt pathway. Toxicol Appl Pharmacol. 2008;228:256–268. [PubMed]
22. Lee CW, Lin CC, Lin WN, Liang KC, Luo SF, Wu CB, Wang SW, Yang CM. TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappaB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L799–812. [PubMed]
23. Javazon EH, Colter DC, Schwarz EJ, Prockop DJ. Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells. Stem Cells. 2001;19:219–225. [PubMed]
24. Toyota E, Warltier DC, Brock T, Ritman E, Kolz C, O'Malley P, Rocic P, Focardi M, Chilian WM. Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation. 2005;112:2108–2113. [PubMed]
25. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 2000;102:E73–86. [PubMed]
26. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005;111:150–156. [PubMed]
27. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368. [PubMed]
28. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg. 2006;30:353–361. [PubMed]
29. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80:229–236. discussion 236-227. [PubMed]
30. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells. 2007;25:2896–2902. [PubMed]
31. Chalothorn D, Moore SM, Zhang H, Sunnarborg SW, Lee DC, Faber JE. Heparin-binding epidermal growth factor-like growth factor, collateral vessel development, and angiogenesis in skeletal muscle ischemia. Arterioscler Thromb Vasc Biol. 2005;25:1884–1890. [PubMed]
32. Arkonac BM, Foster LC, Sibinga NE, Patterson C, Lai K, Tsai JC, Lee ME, Perrella MA, Haber E. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem. 1998;273:4400–4405. [PubMed]
33. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res. 2001;88:22–29. [PubMed]
34. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344–10349. [PubMed]
35. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664–668. [PubMed]
36. Chien KR. Stem cells: lost in translation. Nature. 2004;428:607–608. [PubMed]
37. Limbourg FP, Drexler H. Bone marrow stem cells for myocardial infarction: effector or mediator? Circ Res. 2005;96:6–8. [PubMed]
38. Prockop DJ. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs) Clin Pharmacol Ther. 2007;82:241–243. [PubMed]
39. Rocic P, Kolz C, Reed R, Potter B, Chilian WM. Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am J Physiol Heart Circ Physiol. 2007;292:H2729–2736. [PubMed]
40. Chalothorn D, Clayton JA, Zhang H, Pomp D, Faber JE. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics. 2007;30:179–191. [PubMed]
41. Helisch A, Wagner S, Khan N, Drinane M, Wolfram S, Heil M, Ziegelhoeffer T, Brandt U, Pearlman JD, Swartz HM, Schaper W. Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol. 2006;26:520–526. [PubMed]